Randomized Phase 2 Trial of 177Lu Radiolabeled Anti-PSMA Biochemically Monoclonal Antibody J591 in Patients with High-Risk Castrate, Biochemically Relapsed Prostate Cancer

摘要

Clinical trial has received WCMC IRB and CTSC approval with enrollment of initial 3 subjects. Initial report submitted to WCMC DSMB with recommendation to proceed with enrollment.